BACKGROUND AND OBJECTIVE: The current standard for diagnosis of skin cancers is visual inspection followed by biopsy and histopathology. This process can be invasive, subjective, time consuming, and costly. Optical techniques, including Optical Coherence Tomography (OCT) and Raman Spectroscopy (RS), have been developed to perform non-invasive characterization of skin lesions based on either morphological or biochemical features of disease. The objective of this work is to report a clinical instrument capable of both morphological and biochemical characterization of skin cancers with RS-OCT. MATERIALS AND METHODS: The portable instrument utilizes independent 785 nm RS and 1,310 nm OCT system backbones. The two modalities are integrated in a 4″ (H) × 5″(W) × 8″(L) clinical probe. The probe enables sequential acquisition of co-registered OCT and RS data sets. The axial response of the RS collection in the skin was estimated using scattering phantoms. In addition, RS-OCT data from patients with cancerous and non-cancerous lesions are reported. RESULTS: The RS-OCT instrument is capable of screening areas as large as 15 mm (transverse) by 2.4 mm (in depth) at up to 8 frames/second with OCT, and identifying locations to perform RS. RS signal is collected from a 44 µm transverse spot through a depth of approximately 530 µm. RS-OCT data sets from a superficial scar and a nodular BCC are reported to demonstrate the clinical potential of the instrument. CONCLUSION: The RS-OCT instrument reported here is capable of morphological and biochemical characterization of cancerous skin lesions in a clinical setting. OCT can visualize microstructural irregularities and perform an initial morphological analysis of the lesion. The images can be used to guide acquisition of biochemically specific Raman spectra. The two data sets can then be evaluated with respect to one another to take advantage of the mutually complimentary nature of RS and OCT.
BACKGROUND AND OBJECTIVE: The current standard for diagnosis of skin cancers is visual inspection followed by biopsy and histopathology. This process can be invasive, subjective, time consuming, and costly. Optical techniques, including Optical Coherence Tomography (OCT) and Raman Spectroscopy (RS), have been developed to perform non-invasive characterization of skin lesions based on either morphological or biochemical features of disease. The objective of this work is to report a clinical instrument capable of both morphological and biochemical characterization of skin cancers with RS-OCT. MATERIALS AND METHODS: The portable instrument utilizes independent 785 nm RS and 1,310 nm OCT system backbones. The two modalities are integrated in a 4″ (H) × 5″(W) × 8″(L) clinical probe. The probe enables sequential acquisition of co-registered OCT and RS data sets. The axial response of the RS collection in the skin was estimated using scattering phantoms. In addition, RS-OCT data from patients with cancerous and non-cancerous lesions are reported. RESULTS: The RS-OCT instrument is capable of screening areas as large as 15 mm (transverse) by 2.4 mm (in depth) at up to 8 frames/second with OCT, and identifying locations to perform RS. RS signal is collected from a 44 µm transverse spot through a depth of approximately 530 µm. RS-OCT data sets from a superficial scar and a nodular BCC are reported to demonstrate the clinical potential of the instrument. CONCLUSION: The RS-OCT instrument reported here is capable of morphological and biochemical characterization of cancerous skin lesions in a clinical setting. OCT can visualize microstructural irregularities and perform an initial morphological analysis of the lesion. The images can be used to guide acquisition of biochemically specific Raman spectra. The two data sets can then be evaluated with respect to one another to take advantage of the mutually complimentary nature of RS and OCT.
Authors: Shovan K Majumder; Matthew D Keller; Fouad I Boulos; Mark C Kelley; Anita Mahadevan-Jansen Journal: J Biomed Opt Date: 2008 Sep-Oct Impact factor: 3.170
Authors: Mette Mogensen; Thomas Martini Joergensen; Birgit Meincke Nürnberg; Hanan Ahmad Morsy; Jakob B Thomsen; Lars Thrane; Gregor B E Jemec Journal: Dermatol Surg Date: 2009-04-08 Impact factor: 3.398
Authors: Chad A Lieber; Shovan K Majumder; Dean Billheimer; Darrel L Ellis; Anita Mahadevan-Jansen Journal: J Biomed Opt Date: 2008 Mar-Apr Impact factor: 3.170
Authors: Lida P Hariri; Alexandre R Tumlinson; David G Besselsen; Urs Utzinger; Eugene W Gerner; Jennifer K Barton Journal: Lasers Surg Med Date: 2006-04 Impact factor: 4.025
Authors: Thilo Gambichler; Philipp Regeniter; Falk G Bechara; Alexej Orlikov; Remus Vasa; Georg Moussa; Markus Stücker; Peter Altmeyer; Klaus Hoffmann Journal: J Am Acad Dermatol Date: 2007-07-03 Impact factor: 11.527
Authors: Thomas Martini Jørgensen; Andreas Tycho; Mette Mogensen; Peter Bjerring; Gregor B E Jemec Journal: Skin Res Technol Date: 2008-08 Impact factor: 2.365
Authors: Mette Mogensen; Lars Thrane; Thomas M Jørgensen; Peter E Andersen; Gregor B E Jemec Journal: J Biophotonics Date: 2009-07 Impact factor: 3.207
Authors: Jason R Maher; Oranat Chuchuen; Marcus H Henderson; Sanghoon Kim; Matthew T Rinehart; Angela D M Kashuba; Adam Wax; David F Katz Journal: Biomed Opt Express Date: 2015-05-08 Impact factor: 3.732
Authors: Sebina Shrestha; Michael J Serafino; Jesus Rico-Jimenez; Jesung Park; Xi Chen; Siqin Zhaorigetu; Brian L Walton; Javier A Jo; Brian E Applegate Journal: Biomed Opt Express Date: 2016-08-01 Impact factor: 3.732
Authors: Thomas W Bocklitz; Firas Subhi Salah; Nadine Vogler; Sandro Heuke; Olga Chernavskaia; Carsten Schmidt; Maximilian J Waldner; Florian R Greten; Rolf Bräuer; Michael Schmitt; Andreas Stallmach; Iver Petersen; Jürgen Popp Journal: BMC Cancer Date: 2016-07-26 Impact factor: 4.430